Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of ST-067 (Decoy-Resistant IL-18) With Teclistamab in Multiple Myeloma

NCT06588660 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06588660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06588660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of ST-067 (Decoy-Resistant IL-18) With Teclistamab in Multiple Myeloma
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Terminated
Start date
December 18, 2024
Completion date
February 14, 2025
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent multiple myeloma, refractory multiple myeloma